Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands
Thomas E Barta, Carrboro, NC (US); Jonathan W Bourne, Fairport, NY (US); Kyle D Monroe, Pittsford, NY (US); and Michael M Muehlemann, Liverpool, NY (US)
Assigned to SRX CARDIO, LLC, Pittsford, NY (US)
Filed by SRX CARDIO, LLC, Pittsford, NY (US)
Filed on May 18, 2021, as Appl. No. 17/323,260.
Application 17/323,260 is a continuation of application No. 16/863,530, filed on Apr. 30, 2020, granted, now 11,026,957.
Application 16/863,530 is a continuation of application No. 16/380,414, filed on Apr. 10, 2019, granted, now 10,688,114, issued on Jun. 23, 2020.
Application 16/380,414 is a continuation of application No. 15/989,360, filed on May 25, 2018, granted, now 10,307,433, issued on Jun. 4, 2019.
Application 15/989,360 is a continuation of application No. 15/505,017, granted, now 10,034,892, issued on Jul. 31, 2018, previously published as PCT/US2015/046145, filed on Aug. 20, 2015.
Claims priority of provisional application 62/133,093, filed on Mar. 13, 2015.
Claims priority of provisional application 62/040,264, filed on Aug. 21, 2014.
Prior Publication US 2021/0275551 A1, Sep. 9, 2021
1. A method, comprising binding an allosteric small molecule to a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) protein of a subject with a metabolic disease and modulating the uptake of a low-density lipoprotein by a plurality of hepatocytes.